Methotrexat Al

Methotrexate, the active ingredient in Methotrexat Al, is an antimetabolite (folate antagonist) presented as an injectable formulation for intramuscular and subcutaneous use. It is employed in the management of rheumatoid arthritis, severe psoriasis, acute lymphoblastic leukemia, non‑Hodgkin lymphoma and osteosarcoma, providing disease‑modifying effects in these conditions.

GNH USA supplies Methotrexat Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution and regulatory compliance.

Methotrexate is used across several autoimmune and oncologic disease pathways, offering disease‑modifying benefits. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage. - Psoriasis: limits skin cell proliferation and improves plaque severity. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: impedes tumor growth and induces apoptosis. - Osteosarcoma: hampers DNA synthesis in bone‑origin cancer cells.

Methotrexate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Elevated liver enzymes. - Transient cytopenias. - Alopecia.

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening bone‑marrow suppression. - Acute renal failure. - Severe cutaneous reactions such as Stevens‑Johnson syndrome. - Opportunistic infections due to immunosuppression.

Before initiating therapy, clinicians should evaluate baseline organ function and counsel patients on risk mitigation. - Monitor liver function: perform baseline and periodic LFTs. - Assess renal function: adjust dose or avoid if creatinine clearance is reduced. - Check blood counts: monitor for neutropenia, anemia and thrombocytopenia. - Avoid in pregnancy: drug is teratogenic and contraindicated. - Use effective contraception: both males and females must employ reliable methods during treatment and for several months after cessation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of renal toxicity. - Aminoglycoside antibiotics: potentiate nephrotoxic effects. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Sulfonamide antibiotics: may augment myelosuppression. - Phenytoin: can reduce methotrexate plasma concentrations. - Proton pump inhibitors: may affect gastrointestinal absorption.